Reduction of COVID 19 Transmission to Health Care Professionals

Not Applicable

Completed

• Conditions: COVID 19
• Interventions: Diagnostic Test: Blood group determination; Diagnostic Test: Antibody titration; Dietary Supplement: Probiotic

• Registration Number: NCT04462627
• Lead Sponsor: Hanane EL KENZ

Brief Summary

When the COVID-19 virus infects a person, it enters the lung epithelial cells of its host and uses its genetic material to replicate.

The pulmonary epithelial cells of a part of the population, known as "secretors", are capable of expressing the antigens of the "ABO" system on their surface. This secretory status can be established by determining the antigens of the Lewis blood group system. When the virus replicates in an "secreting" individual, the antigens of the "ABO" system of the infected individual will be present on the surface of the viruses formed in his/her lungs.

It was shown in 2003 that the response of a given individual to the transmission of a virus depends on his/her blood group and on the antigens of the "ABO" system carried by the virus. A patient of group "O" would thus defend himself much better against a virus carrying antigens of blood group "A", the natural antibodies "anti-A" of the patient reducing the ability of the virus to bind to its specific receptor on pulmonary epithelial cells, to penetrate them to replicate itself. The first data collected in Wuhan (China) seems to confirm this hypothesis. A COVID-19 virus transmission model can therefore be established on the basis of blood groups.

In order to reduce the spread of the virus among nursing staff, it is possible to establish a preferential algorithm for patient management based on the "ABO" and "Lewis" blood groups of patients and "ABO" of nursing staff in health care units, if operational and human conditions allow.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-14
• Study First Submitted: 2020-07-07
• Study First Submitted QC: 2020-07-07
• Study First Posted: 2020-07-08
• Primary Completion: 2022-04-11
• Study Completion: 2022-04-11
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-19
• Last Update Posted: 2022-07-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 566

Inclusion Criteria

• COVID19 positive patients admitted within the CHU Brugmann Hospital

Exclusion Criteria

• None

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Untested healthy volunteers	Blood group determination	-
Covid 19 negative patients	Blood group determination	-
Untested healthy volunteers	Antibody titration	-
Covid 19 positive patients	Blood group determination	-
Untested healthy volunteers	Probiotic	-
Covid 19 positive patients	Antibody titration	-
Covid 19 negative patients	Antibody titration	-

Primary Outcome Measures

Name	Time	Method
Anti-A antibody concentration	Week 3	Anti-A antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Anti-B antibody concentration	Week 3	Anti-B antibody titration, as determined by gel agglutination on the Biorad IH-500 automated system.
Blood group	baseline	Blood group (ABO/LE)

Trial Locations

Locations (1)

CHU Brugmann; 🇧🇪 Brussels, Belgium